Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.42 |
| ▸ | FABP1 | P07148 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718135 | 0.87 | PPARG (0.46) | PPARAPPARGFFAR4FFAR1LTB4R | |
| SCHEMBL8908445 | 0.78 | L3MBTL1 (0.53) | — | |
| SCHEMBL7614855 | 0.78 | LMNA (0.49) | PPARAPPARGFABP1DHFR | |
| SCHEMBL584885 | 0.77 | TSHR (0.50) | — | |
| SCHEMBL17651797 | 0.77 | LMNA (0.40) | — | |
| SCHEMBL17651767 | 0.77 | LMNA (0.40) | — | |
| SCHEMBL19718115 | 0.77 | CYSLTR2 (0.47) | PPARAPPARGCYSLTR2CYSLTR1PDE3B | |
| SCHEMBL6851875 | 0.77 | PLA2G4B (0.44) | PDE3BPDE3A | |
| SCHEMBL6851520 | 0.77 | PLA2G4B (0.44) | PDE3BPDE3A | |
| SCHEMBL6847323 | 0.77 | PLA2G4B (0.44) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC | 2019-06-20 | — | — | US | disclosed |
| EP-3471774-A1 | PORPHYRIN COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING CANCER | Oncoselect Therapeutics, LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017218959-A1 | PORPHYRIN COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING CANCER | ONCOSELECT THERAPEUTICS, LLC (US) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | PPARA 4448/4885PPARG 3665/4885FFAR4 4678/4885 |
| US-11590233-B2 | Porphyrin compounds and compositions useful for treating cancer | KIT, HCCS, PPIF | PPARA 4448/4885PPARG 3665/4885FFAR4 4678/4885 |
| US-20190184021-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | TK2, KIT, HCCS | PPARA 4131/4885PPARG 3635/4885FFAR4 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.